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Despite great efforts to the contrary, the molecular basis
underlying schizophrenia and many other psychiatric
disorders remainselusive. Examination of the nonpsychi-
atric manifestations that sometimes accompany schizo-
phrenia provides opportunities to more fully explore
the scope of biochemical and metabolic abnormalities
characterizing the disease spectrum. This issue of the
Journal features a series of articles that focus on the
systemic manifestations of schizophrenia.
A more complete understanding of disease spectrum
can provide important insights into disease etiology.
For example, pathologic analyses of atherosclerotic vas-
cular tissue revealed the presence of immune infiltrates,
thereby helping to revamp our view of coronary artery
disease as an inflammatory disease.
1 In the psychiatric
field, nonpsychiatric dimensions to schizophrenia have
been well described, including a long-recognized associ-
ation between diabetes and schizophrenia.
2 While in-
triguing, the mechanisms that underlie this association
are unclear. While there is little evidence that glucose
intolerance itself may increase schizophrenia risk, one
possibility is that the co-occurrence of diabetes and
schizophrenia could be due to shared environmental/life-
style factors that predispose subjects to both disorders.
This possibility is supported by observations that newly
diagnosed and/or drug-naive schizophrenia patients have
higher than expected rates of glucose intolerance and/or
diabetes.
3,4 Alternatively, schizophrenia could increase
risk of diabetes through reduced physical activity and
concomitant obesity or via insulin desensitizing or weight
gain promoting effects of antipsychotic medications.
There is also a possibility that a shared genetic suscep-
tibility characterizes both diabetes and schizophrenia, as
has been suggested by a small number of family studies,
with limited sample sizes, showing that first-degree rela-
tives of schizophrenia patients have higher than expected
prevalence of type 2 diabetes (eg, Fernandez-Egea et al,
5
Ryan and Collins,
6 and Spelman et al
7). If there are genes
thatjointlyinfluenceschizophreniaanddiabetessusceptibil-
ity,whataretheyandwhatmighttheydo?Somerecentdata
suggest a common pathway might involve regulation of
mitochondrial oxidative energy metabolism.
8 However,
identifyingthespecificgenesinvolvedislikelytobedifficult.
Of the 20 or so bona fide diabetes susceptibility genes
identified to date,
9none have been implicated in psychiatric
disease etiology. Genetic linkage studies, however, have
identified some chromosomal regions in common to both
disorders, including chromosome 1q21–25.
10,11 This region
contains a large number of genes, some with potential joint
effects on both metabolic and psychiatric outcomes, such
asNOS1AP(carboxy-terminalPDZligandofneuronalnitric
oxidesynthase,alsoknownasCAPON),forwhichpolymor-
phisms have been associated with schizophrenia
12 and car-
diac repolarization,
13,14 although not yet firmly with type 2
diabetes. Whether polymorphisms in NOS1AP or in any
other gene will ultimately show joint and robust association
to both diabetes and schizophrenia remains to be seen, but
whenfound,suchobservationscouldprovidevaluableclues
to unraveling the overlap between these disorders.
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